Elevance Health (ELV) Stock
Large US health insurer with Medicare and Medicaid plans. Here's the price, business snapshot, and what's worth knowing about Elevance Health in August 2026.
Elevance Health, Inc (ticker: ELV) is a large-cap US health-insurance conglomerate offering managed-care plans, Medicare and Medicaid services, and a growing set of digital and value-based care solutions. With a market capitalisation of about $77.73B, the company generates revenue from premiums, care-management services and partnerships with providers. Key drivers include membership growth—especially in Medicare Advantage and Medicaid—cost-management efforts and investments in data and digital tools. Investors should note exposure to medical-cost trends, regulatory change and reimbursement pressures, which can affect margins and earnings volatility. The business has scale and diversification across commercial and government programmes, but returns are not guaranteed and share prices can fall as well as rise. This summary is for general educational purposes only and is not personalised investment advice; investors should consider their own risk tolerance, diversification needs and consult a financial adviser where appropriate.
Why It’s Moving
ELV stays in focus as strong earnings and steady analyst support keep the bull case alive
- Analysts remain constructive after Elevance Health’s second-quarter results topped expectations, reinforcing the view that earnings momentum is still holding up even as bottom-line growth eased year over year.
- The stock has continued to trade near the $400 level, suggesting investors are leaning on the company’s recent profitability and guidance strength rather than focusing only on short-term share-price swings.
- Fresh note activity has kept sentiment positive, with new investment positions and broad buy ratings signaling that institutions still see room for the healthcare insurer’s fundamentals to re-rate.
ELV stays in focus as strong earnings and steady analyst support keep the bull case alive
- Analysts remain constructive after Elevance Health’s second-quarter results topped expectations, reinforcing the view that earnings momentum is still holding up even as bottom-line growth eased year over year.
- The stock has continued to trade near the $400 level, suggesting investors are leaning on the company’s recent profitability and guidance strength rather than focusing only on short-term share-price swings.
- Fresh note activity has kept sentiment positive, with new investment positions and broad buy ratings signaling that institutions still see room for the healthcare insurer’s fundamentals to re-rate.
Sixth Month Growth Performance
When is the next earnings date for ELEVANCE HEALTH INC (ELV)?
ELV’s next earnings release is expected on October 21, 2026. It will cover Q3 2026 results, based on the company’s established late-October reporting pattern. Management has typically reported before the market opens, with the conference call following that morning.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Elevance Health’s stock with a target price of $482.97, indicating potential growth.
Financial Health
Elevance Health is performing well with strong revenue and cash generation, indicating solid financial health.
Dividend
Elevance Health's dividend yield of 1.63% is moderate, making it a decent choice for dividend-seeking investors. If you invested $1000 you would be paid $16.86 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Membership Growth Drivers
Medicare Advantage and Medicaid enrolment trends can support revenue expansion, though membership quality and medical costs influence outcomes.
US Market Exposure
Elevance is focused on the US health ecosystem and benefits from demographic ageing, but it remains sensitive to domestic policy and regulation.
Digital Innovation Push
Investments in data and care-management tech aim to reduce costs and improve outcomes, though execution and competition present ongoing risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
